vs
Nutex Health, Inc.（NUTX）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Nutex Health, Inc.的1.4倍（$219.9M vs $151.7M），Nutex Health, Inc.净利率更高（7.8% vs -1.0%，领先8.8%），Orthofix Medical Inc.同比增速更快（2.0% vs -41.1%），Nutex Health, Inc.自由现金流更多（$69.0M vs $16.8M），过去两年Nutex Health, Inc.的营收复合增速更高（50.0% vs 8.0%）
Nutex Health是一家总部位于美国得克萨斯州休斯敦的营利性医疗企业，核心业务为运营各类医疗机构，是美国本土医疗领域的专业运营机构，致力于为当地市场提供相关医疗服务与场地运营支持。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NUTX vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$151.7M
营收增速更快
OFIX
高出43.1%
-41.1%
净利率更高
NUTX
高出8.8%
-1.0%
自由现金流更多
NUTX
多$52.2M
$16.8M
两年增速更快
NUTX
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $219.9M |
| 净利润 | $11.8M | $-2.2M |
| 毛利率 | 30.4% | 71.1% |
| 营业利润率 | 20.4% | 0.2% |
| 净利率 | 7.8% | -1.0% |
| 营收同比 | -41.1% | 2.0% |
| 净利润同比 | -80.8% | 92.4% |
| 每股收益（稀释后） | $2.34 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NUTXOFIX
| Q4 25 | $151.7M | $219.9M | ||
| Q3 25 | $267.8M | $205.6M | ||
| Q2 25 | $244.0M | $203.1M | ||
| Q1 25 | $211.8M | $193.6M | ||
| Q4 24 | $257.6M | $215.7M | ||
| Q3 24 | $78.8M | $196.6M | ||
| Q2 24 | $76.1M | $198.6M | ||
| Q1 24 | $67.5M | $188.6M |
净利润NUTXOFIX
| Q4 25 | $11.8M | $-2.2M | ||
| Q3 25 | $55.4M | $-22.8M | ||
| Q2 25 | $-17.7M | $-14.1M | ||
| Q1 25 | $21.2M | $-53.1M | ||
| Q4 24 | $61.6M | $-29.1M | ||
| Q3 24 | $-8.8M | $-27.4M | ||
| Q2 24 | $-364.0K | $-33.4M | ||
| Q1 24 | $-364.0K | $-36.0M |
毛利率NUTXOFIX
| Q4 25 | 30.4% | 71.1% | ||
| Q3 25 | 57.8% | 72.2% | ||
| Q2 25 | 51.2% | 68.7% | ||
| Q1 25 | 55.9% | 62.8% | ||
| Q4 24 | 55.0% | 69.0% | ||
| Q3 24 | 27.8% | 68.7% | ||
| Q2 24 | 29.7% | 67.8% | ||
| Q1 24 | 15.1% | 67.5% |
营业利润率NUTXOFIX
| Q4 25 | 20.4% | 0.2% | ||
| Q3 25 | 48.7% | -8.3% | ||
| Q2 25 | 13.8% | -7.9% | ||
| Q1 25 | 38.1% | -25.2% | ||
| Q4 24 | 44.4% | -5.3% | ||
| Q3 24 | 12.3% | -9.6% | ||
| Q2 24 | 7.0% | -12.5% | ||
| Q1 24 | 2.1% | -15.6% |
净利率NUTXOFIX
| Q4 25 | 7.8% | -1.0% | ||
| Q3 25 | 20.7% | -11.1% | ||
| Q2 25 | -7.3% | -6.9% | ||
| Q1 25 | 10.0% | -27.4% | ||
| Q4 24 | 23.9% | -13.5% | ||
| Q3 24 | -11.2% | -13.9% | ||
| Q2 24 | -0.5% | -16.8% | ||
| Q1 24 | -0.5% | -19.1% |
每股收益（稀释后）NUTXOFIX
| Q4 25 | $2.34 | $-0.05 | ||
| Q3 25 | $7.76 | $-0.57 | ||
| Q2 25 | $-2.95 | $-0.36 | ||
| Q1 25 | $3.33 | $-1.35 | ||
| Q4 24 | $11.56 | $-0.76 | ||
| Q3 24 | $-1.72 | $-0.71 | ||
| Q2 24 | $-0.07 | $-0.88 | ||
| Q1 24 | $-0.08 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $185.6M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $329.4M | $450.0M |
| 总资产 | $918.5M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NUTXOFIX
| Q4 25 | $185.6M | $82.0M | ||
| Q3 25 | $166.0M | $62.9M | ||
| Q2 25 | $96.7M | $65.6M | ||
| Q1 25 | $84.7M | $58.0M | ||
| Q4 24 | $40.6M | $83.2M | ||
| Q3 24 | $46.9M | $30.1M | ||
| Q2 24 | $40.8M | $26.4M | ||
| Q1 24 | $30.0M | $27.0M |
总债务NUTXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益NUTXOFIX
| Q4 25 | $329.4M | $450.0M | ||
| Q3 25 | $317.2M | $442.5M | ||
| Q2 25 | $235.3M | $458.3M | ||
| Q1 25 | $176.9M | $458.3M | ||
| Q4 24 | $132.4M | $503.1M | ||
| Q3 24 | $60.4M | $525.9M | ||
| Q2 24 | $62.7M | $546.0M | ||
| Q1 24 | $63.0M | $570.3M |
总资产NUTXOFIX
| Q4 25 | $918.5M | $850.6M | ||
| Q3 25 | $964.5M | $832.6M | ||
| Q2 25 | $841.0M | $837.2M | ||
| Q1 25 | $761.9M | $823.1M | ||
| Q4 24 | $655.3M | $893.3M | ||
| Q3 24 | $438.5M | $867.9M | ||
| Q2 24 | $422.4M | $882.0M | ||
| Q1 24 | $404.3M | $906.0M |
负债/权益比NUTXOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $69.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 45.5% | 7.6% |
| 资本支出强度资本支出/营收 | 0.9% | 4.9% |
| 现金转化率经营现金流/净利润 | 5.95× | — |
| 过去12个月自由现金流最近4个季度 | $245.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NUTXOFIX
| Q4 25 | $70.4M | $27.7M | ||
| Q3 25 | $99.5M | $12.4M | ||
| Q2 25 | $27.3M | $11.6M | ||
| Q1 25 | $51.0M | $-18.4M | ||
| Q4 24 | $54.0K | $23.7M | ||
| Q3 24 | $6.8M | $11.7M | ||
| Q2 24 | $13.3M | $9.0M | ||
| Q1 24 | $3.1M | $-18.6M |
自由现金流NUTXOFIX
| Q4 25 | $69.0M | $16.8M | ||
| Q3 25 | $99.2M | $2.5M | ||
| Q2 25 | $26.5M | $4.5M | ||
| Q1 25 | $50.9M | $-25.1M | ||
| Q4 24 | $-341.0K | $15.2M | ||
| Q3 24 | $6.2M | $6.3M | ||
| Q2 24 | $12.7M | $-360.0K | ||
| Q1 24 | $2.3M | $-29.1M |
自由现金流率NUTXOFIX
| Q4 25 | 45.5% | 7.6% | ||
| Q3 25 | 37.0% | 1.2% | ||
| Q2 25 | 10.9% | 2.2% | ||
| Q1 25 | 24.0% | -13.0% | ||
| Q4 24 | -0.1% | 7.0% | ||
| Q3 24 | 7.8% | 3.2% | ||
| Q2 24 | 16.7% | -0.2% | ||
| Q1 24 | 3.4% | -15.4% |
资本支出强度NUTXOFIX
| Q4 25 | 0.9% | 4.9% | ||
| Q3 25 | 0.1% | 4.8% | ||
| Q2 25 | 0.3% | 3.5% | ||
| Q1 25 | 0.0% | 3.5% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 0.7% | 4.7% | ||
| Q1 24 | 1.1% | 5.6% |
现金转化率NUTXOFIX
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
